Highlights of This Issue 243

REVIEW

245 FOX(M1) News—It Is Cancer
Marianna Halasi and Andrei L. Gartel

CHEMICAL THERAPEUTICS

255 A Second-Generation 2-Methoxyestradiol Prodrug Is Effective against Barrett’s Adenocarcinoma in a Mouse Xenograft Model

264 Interaction of the Sympathetic Nerve with Pancreatic Cancer Cells Promotes Perineural Invasion through the Activation of STAT3 Signaling
Kun Guo, Qingyong Ma, Junhui Li, Zheng Wang, Tao Shan, Wei Li, QinHong Xu, and Keping Xie

274 Sensitization of TRAIL-Induced Cell Death by 20(S)-Ginsenoside Rg3, via CHOP-Mediated DR5 Upregulation in Human Hepatocellular Carcinoma Cells
Ju-Yeon Lee, Kyung Hee Jung, Michael J. Morgan, Yi-Rae Kang, Hee-Seung Lee, Gi-Bang Koo, Soon-Sun Hong, Sung Won Kwon, and You-Sun Kim

LARGE MOLECULE THERAPEUTICS

286 Targeted Degradation of KRAS by an Engineered Ubiquitin Ligase Suppresses Pancreatic Cancer Cell Growth In Vitro and In Vivo
Yihui Ma, Yumei Gu, Qiang Zhang, Yongqing Han, Shuangni Yu, Zhaohui Lu, and Jie Chen

295 Neutralization of Prolactin Receptor Function by Monoclonal Antibody LFA102, a Novel Potential Therapeutic for the Treatment of Breast Cancer
Jason S. Damiano, Katherine G. Rendahl, Christopher Karim, Millicent G. Embry, Majid Ghoddusi, Jocelyn Holash, Abdallah Fanidi, Tinya J. Abrams, and Judith A. Abraham

306 Selective Photodetection and Photodynamic Therapy for Prostate Cancer through Targeting of Proteolytic Activity
Maria-Fernanda Zuluaga, Nawal Sekkat, Doris Gabriel, Hubert van den Bergh, and Norbert Lange

CANCER THERAPEUTICS INSIGHTS

314 Dual Programmed Cell Death Pathways Induced by p53 Transactivation Overcome Resistance to Oncolytic Adenovirus in Human Osteosarcoma Cells
Joe Hasei, Tsuyoshi Sasaki, Hiroshi Tazawa, Shuhei Osaki, Yasuaki Yamakawa, Toshiyuki Kunisada, Aki Yoshida, Yuuri Hashimoto, Teppei Onishi, Futoshi Uno, Shunsuke Kagawa, Yasuo Urata, Toshihumi Ozaki, and Toshiyoshi Fujiiwara

326 YM-155 Potentiates the Effect of ABT-737 in Malignant Human Glioma Cells via Survivin and Mcl-1 Downregulation in an EGFR-Dependent Context
Esther P. Jane, Daniel R. Premkumar, Joseph D. DiDomenico, Bo Hu, Shi-Yuan Cheng, and Ian F. Pollack
2-ME2-PD1, a novel prodrug of 2-ME2, has significant antitumorigenic properties with superior bioavailability. Like 2-ME2, 2-ME2-PD1 can also inhibit proliferation and growth of BAC cells. It is well established that antimitotic and antiproliferative action of 2-ME2 is mediated via microtubule disruption. By immunofluorescence, it has been confirmed that, on treatment of BAC cells with 2-ME2-PD1, a dose-dependent disruption of cellular microtubules is taking place, which is associated with the change of cellular morphology and loss of cellular integrity. Thus, like 2-ME2, 2-ME2-PD1 may impart its antiproliferative activity on OE33 cells by targeting the cellular microtubules. This work was specifically carried out by Amlan Das, one of the authors of this article. For details, see article by Kambhampati on page 255.